Staphylococcus aureus
StaphVAX Elicits Antibodies With In Vitro Activity Against Antibiotic-Resistance
Published in TB and Outbreaks Week, March 13th, 2001
New in vitro data confirm that human antibodies elicited by NabiR StaphVAXR (Staphylococcus aureus Polysaccharide Conjugate Vaccine), an investigational vaccine under development to protect at-risk patients from S. aureus blood infections, might be able to combat both antibiotic-resistant as well as antibiotic-sensitive strains of the bacteria.
The new laboratory findings were presented February 22, 2001, at the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting in Atlanta, Georgia. Gary Horwith, MD, Nabi, discussed the research.
Antibiotic resistance in S....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Mycobacterium tuberculosis
New Technique Quickly Identifies Rifampin Resistance In DNA - Outbreaks
Aftermath Of Natural Disasters Poses Major Health Risks - Influenza
Therapy Most Effective When Administered Soon After Symptom Onset - Tuberculosis
Questionnaire Valuable Indicator Of Which Children Should Get Skin Test - Antibiotic Resistance
Human Gut Potential Site For Gene Transfer - Bioterrorism
Researchers Say Botulinum Toxin Is Major Biological Weapons Threat - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
